Dr. David W. Malka, MD

Dr. Malka practices at David W. Malka MD, PA in Hudson, Florida.

Dr. Malka's NPI, 1235176322, was assigned on May 31, 2006. Dr. Malka graduated from Rutgers New Jersey Medical School in 1990. Dr. Malka holds Florida license ME0060892.

Dr. Malka's primary practice is David W. Malka MD, PA, at 7539 Medical Dr, Hudson, FL 34667 in Pasco County. The practice phone is (727) 869-2115.

Dr. Malka's primary practice is David W. Malka MD, PA in Hudson, Florida. Dr. Malka is also affiliated with HCA Florida Oak Hill Hospital. The medical group on file is The Malka Institute of Neuroscience and Disease. Dmand AI also links Dr. Malka to 1 more hospital, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Malka practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Malka's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Malka is board certified in neurology by the American Board of Psychiatry and Neurology. Dr. Malka is licensed in Florida.

Dmand AI lists acute mini-stroke (TIA), alzheimer's disease, carpal tunnel syndrome, cerebrovascular disease, encephalopathy, epilepsy, essential tremor and hereditary polyneuropathy among the conditions Dr. Malka treats.

CMS data shows 1,487 Medicare services from Dr. Malka across 12 procedure codes in 2024, for 514 Medicare patients. Medicare paid $165,453 for them. Every service was in an office.

CMS counts 514 Medicare patients who saw Dr. Malka in 2024. The largest group is 75 to 84, with 224 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 15% are also on Medicaid. Their average risk score is 1.63, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Malka's median patient age at 67, with 57% women.

In 2024, Dr. Malka wrote 2,147 Medicare Part D claims for 478 patients. 89% of them were for generic drugs. CMS names the drug for 1,903 of them, across 44 drugs with 11 or more claims each, at $321,308 in total drug cost. In 2023, CMS named 1,431 claims across 40 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 75 out of 100 for Dr. Malka for performance year 2024, reported individually. Dr. Malka accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 104 papers to Dr. Malka, published from 2005 to 2023. 2014 was the busiest year, with 7. The most frequent topics are Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols and Liver Neoplasms. Dr. Malka has published most often in Eur J Cancer.

CMS Open Payments shows 467 general payments to Dr. Malka from 57 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 97% of the total. Abbvie Inc. paid the most, $867.

Dr. Malka graduated from Rutgers New Jersey Medical School in 1990.

Dr. Malka is in network with 18 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.